NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis $28.95 +0.48 (+1.69%) Closing price 04:00 PM EasternExtended Trading$27.88 -1.07 (-3.71%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Veracyte Stock (NASDAQ:VCYT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Veracyte alerts:Sign Up Key Stats Today's Range$27.50▼$29.4350-Day Range$28.47▼$46.1452-Week Range$18.61▼$47.32Volume1.31 million shsAverage Volume840,330 shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice Target$43.40Consensus RatingModerate Buy Company OverviewVeracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.Read More… Remove Ads Veracyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreVCYT MarketRank™: Veracyte scored higher than 89% of companies evaluated by MarketBeat, and ranked 76th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageVeracyte has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Veracyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth5.88% Earnings GrowthEarnings for Veracyte are expected to grow by 5.88% in the coming year, from $0.68 to $0.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -190.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -190.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Veracyte's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.31% of the float of Veracyte has been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Veracyte has recently decreased by 2.65%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.07 Percentage of Shares Shorted4.31% of the float of Veracyte has been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Veracyte has recently decreased by 2.65%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment1.21 News SentimentVeracyte has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Veracyte this week, compared to 6 articles on an average week.MarketBeat FollowsOnly 2 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,109.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Veracyte is held by insiders.Read more about Veracyte's insider trading history. Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address VCYT Stock News HeadlinesVeracyte Inc.April 4 at 3:12 PM | wsj.comCritical Review: Veracyte (NASDAQ:VCYT) vs. CannLabs (OTCMKTS:CANL)March 31, 2025 | americanbankingnews.comCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see this footage.) A lot of people believe the U.S. government is hiding aliens at the highly classified U.S. Air Force facility in Nevada known as “Area 51.”April 4, 2025 | Brownstone Research (Ad)Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever!March 29, 2025 | msn.comVeracyte (VCYT) Shares Cross Above 200 DMAMarch 27, 2025 | nasdaq.comNew Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder CancerMarch 27, 2025 | finance.yahoo.comNew Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder CancerMarch 25, 2025 | businesswire.comVeracyte initiated with a Buy at Craig-HallumMarch 21, 2025 | markets.businessinsider.comSee More Headlines VCYT Stock Analysis - Frequently Asked Questions How have VCYT shares performed this year? Veracyte's stock was trading at $39.60 at the beginning of the year. Since then, VCYT shares have decreased by 27.9% and is now trading at $28.5360. View the best growth stocks for 2025 here. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) issued its earnings results on Monday, February, 24th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.07. The biotechnology company earned $118.63 million during the quarter, compared to analyst estimates of $110.73 million. Veracyte had a positive trailing twelve-month return on equity of 3.02% and a negative net margin of 2.18%. Does Veracyte have any subsidiaries? Veracyte subsidiaries include HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS. Who are Veracyte's major shareholders? Veracyte's top institutional shareholders include Versant Capital Management Inc. Insiders that own company stock include Rebecca Chambers, John Leite, Giulia C Kennedy, Bonnie H Anderson, Jonathan Wygant, Jonathan Wygant, Evan/ Fa Jones, John L Bishop, Jens Holstein, Muna Bhanji and Karin Eastham. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings2/24/2025Today4/04/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:VCYT CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees790Year Founded2006Price Target and Rating Average Stock Price Target$43.40 High Stock Price Target$51.00 Low Stock Price Target$28.00 Potential Upside/Downside+52.1%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.30 Trailing P/E RatioN/A Forward P/E Ratio41.96 P/E GrowthN/ANet Income$-74,400,000.00 Net Margins-2.18% Pretax Margin-1.92% Return on Equity3.02% Return on Assets2.80% Debt Debt-to-Equity RatioN/A Current Ratio5.08 Quick Ratio4.79 Sales & Book Value Annual Sales$445.76 million Price / Sales4.99 Cash Flow$0.06 per share Price / Cash Flow442.29 Book Value$14.30 per share Price / Book2.00Miscellaneous Outstanding Shares77,945,000Free Float76,493,000Market Cap$2.22 billion OptionableOptionable Beta2.03 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:VCYT) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.